Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation

被引:56
作者
de Otero, J
Gavaldà, J
Murio, E
Vargas, V
Calicó, I
Llopart, L
Rosselló, J
Margarit, C
Pahissa, A
机构
[1] Univ Autonoma Barcelona, Hosp Gen Valle Hebron, Div Infect Dis, Infect Dis Serv, Barcelona 08035, Spain
[2] Univ Autonoma Barcelona, Hosp Gen Valle Hebron, Liver Transplantat Serv, Barcelona 08035, Spain
[3] Univ Autonoma Barcelona, Hosp Gen Valle Hebron, Serv Hepatol, Barcelona 08035, Spain
[4] Univ Autonoma Barcelona, Hosp Gen Valle Hebron, Microbiol Serv, Barcelona 08035, Spain
[5] Univ Autonoma Barcelona, Hosp Gen Valle Hebron, Prevent Med Serv, Barcelona 08035, Spain
关键词
D O I
10.1086/513949
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To determine whether cytomegalovirus (CMV) disease is an independent risk factor for graft loss and death after orthotopic liver transplantation, we performed a 3-year follow-up study of 143 consecutive liver transplant recipients and sis patients who underwent retransplantation. Thirty-seven patients (25%) had had CMV disease and were alive after treatment. Fifty-two deaths and eight graft losses occurred. The cumulative incidence of graft failure at 1 and 3 years of follow-up were 40% and 63%, respectively, for patients with CMV disease, compared with 22% and 33%, respectively, for those without CMV disease (P <.05, logrank test), Cumulative probabilities of survival for patients with and without CMV disease were 64% and 82%. respectively, at 1 year and 46% and 69%, respectively, after 3 years (P <.05, logrank test). Multivariate analysis with use of a time-dependent Cox model showed that previous CMV disease was an independent risk factor for graft loss at 1 and 3 years of follow-up (P = .04 and P = .007) and for patient survival (P = .04 and P = .01). Our results indicate that CMV disease is a significant independent risk factor for graft loss and patient survival after liver transplantation.
引用
收藏
页码:865 / 870
页数:6
相关论文
共 31 条
  • [1] BACKMAN L, 1993, TRANSPLANTATION, V55, P1078
  • [2] BELLE SH, 1993, TRANSPLANT P, V25, P1137
  • [3] BISMUTH H, 1987, LANCET, V2, P674
  • [4] BRONSTHER O, 1995, TRANSPLANT P, V27, P1206
  • [5] CASAVILLA A, 1994, HEPATOLOGY, V20, pA133
  • [6] CASTALDO P, 1991, TRANSPLANT P, V23, P1517
  • [7] Influence of anti-HLA antibodies and positive T-lymphocytotoxic crossmatch on survival and graft rejection in human liver transplantation
    Charco, R
    Vargas, V
    Balsells, J
    Lazaro, JL
    Murio, E
    Jaurrieta, E
    Martorell, J
    Margarit, C
    [J]. JOURNAL OF HEPATOLOGY, 1996, 24 (04) : 452 - 459
  • [8] RISK-FACTORS FOR INVASIVE FUNGAL-INFECTIONS COMPLICATING ORTHOTOPIC LIVER-TRANSPLANTATION
    COLLINS, LA
    SAMORE, MH
    ROBERTS, MS
    LUZZATI, R
    JENKINS, RL
    LEWIS, WD
    KARCHMER, AW
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (03) : 644 - 652
  • [9] ENHANCED RISK OF STEROID-RESISTANT ACUTE REJECTION FOLLOWING PRETRANSPLANT STEROID-THERAPY IN LIVER GRAFT RECIPIENTS
    CONTI, F
    DOUSSET, B
    ARCHAMBEAU, D
    LOUVEL, A
    HOUSSIN, D
    CALMUS, Y
    [J]. TRANSPLANTATION, 1995, 60 (10) : 1104 - 1108
  • [10] ADULT LIVER-TRANSPLANTATION - AN ANALYSIS OF THE EARLY CAUSES OF DEATH IN 40 CONSECUTIVE CASES
    CUERVASMONS, V
    MARTINEZ, AJ
    DEKKER, A
    STARZL, TE
    VANTHIEL, DH
    [J]. HEPATOLOGY, 1986, 6 (03) : 495 - 501